Alira Health says regulatory convergence cuts biosimilar development costs as competition widens

• Alira Health published a 2026 midyear review flagging a new phase in the global biosimilars market as regulation shifts.
• Strategy is moving toward vertical integration as generics groups buy or build development, manufacturing, or commercial scale.
• Regulatory convergence at the FDA and EMA is expected to cut development costs via greater reliance on analytics and pharmacokinetics.
• The FDA estimates a revised comparator approach could reduce pharmacokinetic study costs by up to 50%.
• More than $300 billion in biologic sales could lose exclusivity by 2030, with biosimilar competition still thin across many assets.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alira Health Ventures LLC published the original content used to generate this news brief on October 01, 2026, and is solely responsible for the information contained therein.